Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006–2015
نویسندگان
چکیده
OBJECTIVES To present a snapshot of experimental cardiovascular research with a focus on geographical and temporal patterns of early termination due to poor accrual. SETTING The Aggregate Analysis of ClinicalTrials.gov (AACT) database, reflecting ClinicalTrials.gov as of 27 March 2016. DESIGN The AACT database was searched for all cardiovascular clinical trials that started from January 2006 up to December 2015. RESULTS Thirteen thousand and seven hundred twenty-nine cardiovascular trials were identified. Of these, 8900 (65%) were classified as closed studies. Globally, 11% of closed trials were terminated. This proportion varied from 9.6% to 14% for trials recruiting from Europe and Americas, respectively, with a slightly decreasing trend (p=0.02) over the study period. The most common reason for trials failing to complete was poor accrual (41%). Intercontinental trials exhibited lower figures of poor accrual as the reason for their early stopping, as compared with trials recruiting in a single continent (28% vs 44%, p=0.002). CONCLUSIONS Poor accrual significantly challenges the successful completion of cardiovascular clinical trials. Findings are suggestive of a positive effect of globalisation of cardiovascular clinical research on the achievement of enrolment goals within a reasonable time frame.
منابع مشابه
Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis
BACKGROUND Poor accrual is a significant barrier to the successful completion of oncology clinical trials; half of all phase 3 oncology trials close due to insufficient accrual. Timely access to accrual data fosters an understanding of successful trial design and can be used to inform the design of new clinical trials prospectively. Accrual statistics are available within research networks, suc...
متن کاملTerminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination
BACKGROUND Clinical trials that end prematurely (or "terminate") raise financial, ethical, and scientific concerns. The extent to which the results of such trials are disseminated and the reasons for termination have not been well characterized. METHODS AND FINDINGS A cross-sectional, descriptive study of terminated clinical trials posted on the ClinicalTrials.gov results database as of Febru...
متن کاملClinical trial development as a predictor of accrual performance--letter.
In the November 15, 2010 edition of Clinical Cancer Research, Cheng and colleagues describe an important finding, namely, the association between trial development time and accrual success (1). Their article also reports accrual success rates for NCI Cancer Therapy Evaluation Program (CTEP)-sponsored trials. This publication formally publishes the finding that 40% of cancer clinical trials of a...
متن کاملAchieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
PURPOSE Assessing impact of poor accrual on premature trial closure requires a relevant metric. We propose defining accrual sufficiency on apparent ability to address primary endpoints (PE) rather than attaining accrual targets. EXPERIMENTAL DESIGN All phase III trials open January 1, 1993, to December 31, 2002, by five U.S. oncology Clinical Trials Cooperative Groups (CTCG) were evaluated fo...
متن کاملThe Single Nucleotide Polymorphisms in the C-reactive Protein Gene: are they Biomarkers of Cardiovascular Risk?
Recent pre-clinical and clinical studies have revealed the C-reactive protein gene (CRP) is related to the degree of acute rise in plasma C-reactive protein (CRP) levels. Moreover, single nucleotide polymorphisms (SNPs) in the CRP gene could associate with increased risk of cancer, atherosclerosis, diabetes mellitus, bowel disease, rheumatoid arthritis, psoriasis, obstructive pulmonary disease,...
متن کامل